Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-111 in advanced c-Met over-expressing cancer
NCT02055066Phase 1Completed
- Sponsor
- argenx
- Start
- Jan 2014
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ARGX-111 in cancer (4 arms), sponsored by argenx. Primary endpoint: Dose-limiting toxicity at 1 month. Started Jan 2014; status: completed.
02
Drugs
ARGX-111
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02055066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055066.